Post-Event Report

Biologics Europe Online: Event Highlights and Market Trends

By Tia Byer |
15 July 2021
The first Biologics EU Series to be held virtually, we look back on some of the event’s highlights and discuss some of the key market trends facing Biologics today.

Overview: 

Between 26 – 28 April this year, Oxford Global held its Biologics Europe: Online, consisting of the Proteins & Antibodies Congress, Peptides Congress and the Oligonucleotides Symposium. The virtual congress and exhibition ran over 3 days and showcased a range of industry-leading keynotes, 4 live panel discussions, 4 engaging workshops, 18 Q&A sessions, and 13 roundtable events. Every year our Biologics event series brings together the senior decision-makers from industry, biotech and academia.

2021’s event compromised of over 500 senior attendees from leading pharmaceutical and solution provider companies, as well as academic representatives from some of Europe’s top research institutions.

The event consisted of five key focus areas: ProteinsAntibodies, PeptidesBispecifics, and Oligios, and featured over 50 on-demand sessions. Focused sessions led by thought leaders covered topics relating to the latest market developments and industry challenges, as well as future growth potential. Key speakers included Bruce Carpick (Sanofi Pasteur), Amita Datta-Mannan (Eli Lilly), Kevin McDonnell (Bicycle Therapeutics), Mack Flinspach (Takeda), Katharina Billian-Frey (Apogenix), and Punit Seth (Ionis Pharmaceuticals). In this post-event report, we have gathered some of the highlights from the events, including benefits of attending the conference, a summary of the key topic area discussed, and the major trends facing the Biologics industry today. Whether you joined us for the Biologics Europe: Online event, or want to find out what you missed, we hope this report will encourage you to join us at our hybrid Biologics UK event.  

Benefits to Attending: 

Benefits to attending Biologics Europe included the opportunity to discuss the latest developments and platforms in engineering antibodies, ADCs and bispecifis, as well as emerging computational technologies such as AI and Machine Learning. Delegates were also able to expand their knowledge and find solutions to various challenges facing bioanalysis. These included advanced characterisation, and stability updates, as well as PKPD and the hurdles facing immunogenicity. The event mapped out the latest developments of bispecific antibodies, in addition to that of computer-aided design, purification, and analysis. Delegates were also able to hear about a variety of peptide therapeutic case studies in areas ranging from metabolic disorders to oncology. And the virtual mingling sessions provided the perfect networking opportunity. 

Our Oligonucleotides virtual symposium hosted various meet-and-greets and interactive live Q&As with the leading figures in oligonucleotides chemistry and therapeutics. By gaining insight into the latest synthesis technology and analytical developments, the event provided an opportunity for scientists and industry experts to advance their research and share new ideas. Panel discussions highlighted the key challenges and market trends affecting the latest research into the therapeutic potentials of oligonucleotides, and how best to optimise both their oncological and miRNA application.

Key Topic Areas: Proteins and Antibodies, Bispecifics, Peptides, and Oligonucleotides 

Protein and Antibodies: Key topic areas within the Proteins and Antibodies track included innovative engineering techniques, developability, ADCS, and alternative antibody display technologies. Vaccine development technologies were also a focal point of the discussions. The most popular presentation, with 78 views, was solution provider Lonza’s talk on protein expression. Entitled, ‘Right First Time: Optimise And De-Risk Your Early Development Journey’, Lonza’s Head of Immunology spoke of the need to minimise guesswork during the early drug discovery stage. Lonza highlighted how in silico and in vitro protein design can advance developability by making protein and antibody-based therapies both safer and more efficient. The second most popular presentation; ‘Strategies And Tools To Maximise Successful Development Of Cell Lines Expressing More Complex Proteins’, discussed the need for a multi-faceted engineering approach to Next Generation Biologics. This received 75 views and was presented by the Head of Expression Systems at Lonza.  

Bispecifics: The Bispecifics track took an in-depth look at bispecifics novel discovery and platform development, as well as T-Cell re-direction and T-Cell-engaging molecules and strategies. Merus’s ‘Multiclonics Antibody Platform For Discovery Of Novel Therapeutics’ talk received a total of 61 views. In discussing multispecific antibodies based on the human light chain concept, the Director of Antibody Discovery at Merus presented their cutting-edge platform created to optimise the engineering of potent multispecific antibody molecules. The panel discussion, ‘Bispecific Antibodies Come To The Force’ was the second-best viewed session. Moderated by the Vice President of Alligator Biosciences, the team of panellists were made up of key industry figureheads. These companies included Roche Glycart AG, PIERIS, GlaxoSmithKline, and Sartorius Corporation. It reached over 60 views and looked at the rapidity to which bispecific drugs, particularly those developed for oncological treatment, are entering clinical studies. Key discussion points covered the use of indication and binder selection, how translational model evaluate efficacy and safety, and whether the industry should narrow down bispecific formats.  

Peptides: Within the Peptides track, principal topic areas included peptide chemistry, synthesis, and analytical development. Featured case study presentations looked at the use of bispecific therapeutics for metabolic disorders, immunology, and immune-oncology. Gyros Protein Technologie’s presentation on how peptide-based epitopes and therapeutics are synthesised for COVID-19 provided a fascinating insight into peptides chemistry. The talk, ‘Considerations For Optimising High-Throughput Synthesis Of SARS-CoV-2 Peptides For Epitope Analysis’, racked in an impressive 94 views, making it the most popular session of the entire Biologics Eu event. Bachem’s spotlight presentation on their latest innovations in engineering microspheres and nanoparticles for peptide delivery also attracted a considerable audience. The ‘Spotlight On New Technologies’ session received 80 + views and touched on Bachem’s molecule Hiving technologies, as well as their latest venture into process developments of oligonucleotides and NCEs.  

Oligonucleotides: Finally, the co-located Oligonucleotides: Chemistry & Therapeutics Symposium provided an in-depth analysis of the pressing challenges and opportunities in oligo chemistry, analytical development, and miRNA therapeutics. Among its most noteworthy sessions was the AstraZeneca keynote address and the industry presentation led by Biogen. AstraZeneca’s address, ‘Characterisation Of Therapeutic Oligonucleotides In Early Drug Discovery’ spoke of challenges in LC-MS characterisation of oligonucleotides. The presentation received 90 views and provided interesting industry examples that illustrated both high-throughput and in-depth characterisation of synthetic oligonucleotides. Biogen’s ‘Drive To A More Sustainable Synthesis Of Large-Scale Oligonucleotides’ gained over 80 views. Discussing the drawbacks of using solid-phase synthesis processing to meet large-scale manufacturing demands, the industry presentation proposed a liquid phase synthesis as a more practical and scalable design process.  

Market Trends: Compuatational Engineering, Vaccinology, and ADCS 

Computational Engineering: During the post-event advisory meeting, board members from both leading industries and research institutions discussed the expected key trends facing the biologics market. The top three trends identified were: computational and digitised engineering tools, vaccine development, and the renewed interest in ADCs. Computational engineering or augmented intelligence is a relatively novel discipline in the world of biotherapeutic manufacturing and refers to the development and optimisation of therapeutics using computer-based software. In biologic drug production, computational techniques can be used to assist in the discovery of these therapies by imitating the pre-established design process and synthesis of these biological components. Computation engineering is divided into two main strands: Artificial Intelligence (AI) and Machine Learning (ML). Trying to understand the opportunities that lie within these modalities of rational design is set to become an important and rapidly increasing area of interest. This is not only due to its potential to accelerate mass-scale manufacturing needs, but also the cross-disciplinary prospects it holds for other areas of drug and scientific discovery. 

Vaccinology: Non-surprisingly we can also expect to see a vaccine renaissance occurring. Due to the COVID-19 pandemic and the global race for inoculation, our board members predict that conversations around the use of innovative technology in vaccine discovery will set a precedent in biologics research. It will be the versatility of the vaccine that likely be under discussion. Will these vaccines be able to withstand viral evolution? As new variants of coronavirus SARS-CoV-2 emerge, vaccine developers will have to work to create booster doses to fight its various strains and provide a long-immune response. Much like with other viral infections such as influenza and the flu, where multiple strains mutate every year, the COVID-19 vaccines will have to undergo continual redesign. The rate of deliverability and manufacturing, as well as cost, will prove an area of concern. 

ADCs: According to one board member, the plethora of incoming ADC programmes being approved for the market will produce a renewed interest in the enabling strategies of ADCs. Focus and conversation will pertain to developing the right type of models in the preclinical stage. For example, what happens when data obtained from an animal model in the preclinical stage is encouraging? How representative is it? What happens if it is misleading? As an evolving field, the stability of complex and correct conjugation chemistry remains a developing art. ADC imaging is also a maturing technique used in Biologics discovery. Mass spectrometry imaging is a tool that enables visualisation of the spatial distribution of molecular products to predict the location and movement of cancerous matter. As a non-invasive form of imaging, this tool could be set to transform oncological practices in modern medicine.

These market trends and the important insights provided by the advisory board will inform the structure and content of our next annual Biologics Europe event. In the meantime, however, we hope you can join us at Biologics UK: In-Person on the 6th and 7th September 2021. 

Speaker Biographies

Bruce Carpick, Global Analytics Expert of Biochemistry at Sanofi Pasteur
Dr. Bruce Carpick  joined Sanofi Pasteur R&D, Toronto, Canada in 1998 and leads several cross-functional teams focused on development and implementation of new and innovative analytical technologies. He is a member of the Innovative Medicines Initiative VAC2VAC consortium, the USP Expert Committee on Complex Biologics and Vaccines, and is Secretary and Board Member, IABS North America. 

Amita Datta-Mannan, Senior Research Advisor and Clinical Pharmacologist at Eli Lilly
Dr Amita Datta-Mannan has 17 years of experience as a pharmaceutical scientist leading cross-functional drug discovery and development teams in various technical and corporate leadership roles. She has contributed to discovery of multiple medicinal modalities and developed the first surrogate chemokine receptor structures to dissect the structure-function relationship of receptor-ligand interactions for developing therapies directed at autoimmune disorders.

Kevin McDonnell, Vice President at Bicycle Therapeutics
As Vice President of Chemistry for Bicycle Therapeutics, Dr. McDonnell is responsible for advancing bicyclic peptide therapeutics in the oncology discovery programs, with a focus on immuno-oncology. He began his career developing FcRn targeted peptides and Fc fusion protein therapeutics at Syntonix Pharmaceuticals and Biogen. obtained his PhD with Prof. Barbara Imperiali at MIT. McDonnell has previously worked for BIND Therapeutics where he led the discovery chemistry efforts. 

Mack Flinspach, Director of Structural Biology at Takeda
Mack Flinspach, PhD is a structural biologist and protein and peptide engineer with over 23 years of research experience. He is an experienced group and project leader with a history of working within large and small molecule drug discovery. Flinspach has collaborated within a variety of therapeutic areas, with particular strength in neuroscience and pain. 

Katharina Billian-Frey, Head of Protein Engineering at Apogenix
Katharina Billian-Frey, PhD, joined the Drug Discovery Unit of Apogenix, Germany, in January 2018 as a senior scientist. Billian-Frey is an expert in antibody-based immuno-oncology drugs and protein engineering.  She previously worked as a post-doc at HI-STEM, where she was responsible for the development and maintenance of a drug discovery pipeline for cancer stem-cell derived targets.

Punit Seth, Vice President at Ionis Pharmaceuticals
Dr. Punit Seth has extensive experience with using medicinal chemistry strategies, pharmacokinetic and toxicological properties of oligonucleotide drugs. He is co-inventor of Ionis’ Gen 2.5 platform which employs high affinity nucleoside modifications to enhance the affinity, stability and potency of ASOs in the liver and in extra-hepatic tissues. Seth also co-invented Ionis’ LICA platform, enhancing ASO potency by targeted delivery to cells and tissues of interest.  

Noel Smith, Head of Immunology at Lonza
Noel completed his PhD and subsequent post-doctoral studies at the University of Cambridge in the field of metabolic disease. Smith joined Lonza in 2009 and was involved in the setup of the human primary cell-based assay platform. He now Heads the Immunology group which develops assays to screen products for immunogenicity and immunotoxicity risk. 

Alison Porter, Head of Expression Systems at Lonza
Dr Alison Porter first joined Lonza in 1998 and worked in the Cell Culture Process Development Group, before re-joining in 2026 as Head of Process Development Sciences (PDS). She now serves as the Head of Expression System Sciences, a role that includes providing in-depth scientific and technical leadership to those working with Lonza’s GS Gene Expression System®. Porter specialises in gene expression systems and the development of recombinant cell lines.  

Rinse Klooster, Director of Antibody Discovery at Merus
As Director of the Early Antibody Discovery, Klooster is responsible for the generation of the antigen-specific common light chain based Fab panels that form the basis of Merus’ multispecific antibody platform. Previously he has worked as both an assistant professor at the Department of Human Genetics of the Leiden University Medical Centre, focusing on biomolecular mechanisms behind the IgG4-related muscle diseases, and a senior scientist.  

Peter Ellmark, Vice President of Discovery at Alligator Biosciences
Peter Ellmark joined Alligator Bioscience in 2008 before being appointed Chief Scientific Officer in 2021. He holds a PhD and an associate professorship in Immunotechnology from Lund University and has more than 20 years’ experience in developing antibodies for immunotherapy of cancer. Dr. Ellmark’s research interest is focused on developing mono- and bispecific antibodies, in particular CD40 and 4-1BB targeting therapies, for tumour directed immunotherapy of cancer. 

Christian Klein, Department Head Cancer Immunotherapy at Roche Glycart AG
Christian Klein works as the Head of Oncology Programs, Department Head Cancer Immunotherapy Discovery 3, and Site Head of the Roche Innovation Center Zurich. He specialises in the discovery, engineering, validation and preclinical development of therapeutic (bispecific) antibodies and fusion proteins for Cancer Immunotherapy (CIT). Most notably, Klein made major contributions as a research project leader during the preclinical development and approval of GAZYVA/GAZYVARO. 

Shane Olwill, Senior Vice President and Head of Translational Science at PIERIS
Dr Shane Olwill, PhD, has spent over fifteen years in immunology focused drug discovery with a specific interest in novel biologics. At Pieris Pharmaceuticals Olwill is responsible for target selection and advancement of a pipeline of innovative Anticalin based biologics across Immuno-Oncology and Respiratory disease. He provides strategic oversight and guidance to Therapeutic Area leads and all team members within Translational Science Department. 

Sarah Stuart, HTC Team Leader at GlaxoSmithKline
Sarah Stuart, PhD, joined GSK in 2014 as part of the Biacore and Protein Analytics group in BioPharm Lead Discovery, measuring protein-antibody interactions using surface plasmon resonance (SPR) and biolayer interferometry (BLI). Currently she leads the High Throughput Characterisation team in its aim to o support programmes throughout the antibody discovery process through characterising protein-protein interactions using state-of-the-art SPR technologies. 

Helge Schnerr, Global Marketing at Sartorius Corporation
Dr. Helge Schnerr is Marketing Manager EMEA at Fortébio a business unit of Molecular Devices. He has over 20 years’ experience in research and development, product management and marketing. Before joining Fortébio in 2016, Dr. Schnerr was Head of Marketing for the largest sequencing service provider in Europe. Prior to that Helge spent over 10 years working in the laboratory before taking on his first management position.  

Lukasz Frankiewicz, Senior Product Specialist (EMEA) at Gyros Protein Technologie
Frankiewicz has close to 20 years’ experience working in Peptide Chemistry and obtained his PhD from the University of Warsaw. He has worked as a Post Doc in Belgium and with universities and private companies in Dublin, Ireland. Frankiewicz has also been involved in Project Management of the synthesis of peptides, peptide libraries and the chemical synthesis of proteins with a company in France. 

Claudia Murar, Business Development Manager at Bachem
Claudia Murar, PhD, first joined Bachem in 2018 and has since been made Business Development Manager of new chemical entities, peptides and oligonucleotides. Previously Murar worked as a Pioneer Fellow at ETH Zurich University where she conducted research on developing breakthroughs in the fields of oncology and autoimmune disease. She received her PhD at ETH Zurich and also spent time studying in France, Japan, the UK and the US.  

Zina Zokouri, Business Development Manager at Bachem
Zina Zokouri joined Bachem in 2020 and works as a Business Development Manager. Previously Zokouri has worked for technology firms such as Valantic and Evolva, where she researched metabolic pathway engineering for the biosynthesis of plant-derived compounds in yeast and development of a transcription-factor-based biosensors for the detection of those compounds. 

Seamus White, Business Development Manager at Bachem
Seamus White is a Business Development Manager for Peptides and Oligonucleotide and has over 20 years working in the Pharma and CMO industry. He specialises in HiPo Oncology API, Peptide and ADC warhead and has experience leading SHE and Management Systems Auditor initiatives. White holds a BSc in Chemistry and Pharmacology, and a MCIPs from the Chartered Institute Procurement Supply.  

Tomas Leek, Associate Director at AstraZeneca
As Associate Director at AstraZeneca, Leek leads the Physical and Analytical Characterization team in Medicinal Chemistry. He has over 20-year experience in Analytical Chemistry in early Drug Discovery, and a broad experience of analysis and physicochemical characterisation of compounds in early phase. These include reaction monitoring, batch scale-up support and final characterisation of small molecules, peptides and oligonucleotides. 

Xianglin Shi, Head of Oligonucleotide Chemical Development at Biogen
In his role at Biogen Shi is responsible for oligonucleotide API process development, which includes solid-supported and solution-phase synthesis, and involved in process validation, manufacturing, and worldwide regulatory filing. He first joined Biogen as part of the process chemistry group where he was involved in process R&D, scale-up, manufacturing, and regulatory filing. Shi holds a B.S. in Chemistry, an M.S and a PhD from Emory University.  

Share this article

Share on facebook
Share on twitter
Share on linkedin

You may also be interested in...

Insight Article
At 2021’s Biologics Europe: Online, we sat down with an advisory group of leading industry experts to hear their thoughts on the state of the Biologic drug industry and the potential of Biotherapeutic manufacturing. Biologics engineering is a rapidly evolving field, and 2022 looks to be a year of exciting technological and strategy breakthroughs.
20 August 2021
Insight Article
2020 and 2021 has been dominated by headlines about the COVID inoculation programme and its tremendous success. But what’s next for the vaccine?
16 August 2021

Continue browsing

Share this article

Share on facebook
Share on twitter
Share on linkedin

Join our Biologics mailing list

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biologics

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.